Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patientsFrancesca Gay, Antonio Palumbo, Pellegrino Musto et al.|Blood|2011Cited by 268
Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: Updated Follow-Up and Improved SurvivalAntonio Palumbo, Michèle Cavo, Sara Bringhen et al.|Journal of Clinical Oncology|2014Cited by 210
Bortezomib induction, reduced-intensity transplantation, and lenalidomide consolidation-maintenance for myeloma: updated resultsFrancesca Gay, Antonio Palumbo, Valeria Magarotto et al.|Blood|2013Cited by 82
Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapyFederica Cavallo, Antonio Palumbo, Giuseppe Milone et al.|Leukemia|2011Cited by 63
Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myelomaMarco Ladetto, Benedetto Bruno, Simone Ferrero et al.|Leukemia|2015Cited by 36